ImmVira

Executive Summary

ImmVira is a clinical-stage biotechnology company based in Shanghai, China, specializing in oncolytic virus therapies for cancer treatment. Founded in 2020, the company has raised $100 million to advance its core technology platform, which uses genetically modified herpes simplex virus (HSV) vectors designed to selectively replicate in and destroy tumor cells while stimulating anti-tumor immune responses. ImmVira's pipeline primarily targets solid tumors across multiple cancer types, leveraging the dual mechanism of direct oncolysis and immune activation. The company is currently in Phase 2 clinical development, with a focus on addressing high unmet needs in oncology. Given its innovative approach and significant funding, ImmVira is positioned as a key player in the oncolytic virus space, though it faces competition and regulatory hurdles typical of early-stage biotechs. The company's progress in upcoming clinical milestones will be critical for its valuation and potential partnerships.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical data readout for lead oncolytic HSV candidate in solid tumors70% success
• Q4 2026FDA or NMPA clearance for IND application of a new combination therapy60% success
• TBDAnnouncement of a strategic partnership or licensing deal for ex-China rights50% success